Inspire Medical Systems, Inc. (INSP) - Stock Analysis
Last updated: Apr 4, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Compelling short-term momentum with a 75% price surge over 21 days, driven by Q3 earnings beat, raised EPS guidance, growing Inspire V system adoption, positive reimbursement changes for 2026, but tempered by pending securities class-action risks and margin compression.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠High cash liquidity ⢠Low leverage ⢠High operating costs INSP displays very strong liquidity, cash generation and healthy margins with low leverage, but large absolute operating costs and working-capital ties compress operating income and leave EV multiples elevated versus a modest P/E.
Price Behavior
Key Price Behavior Insights: ⢠Below last month SMA ⢠Low-$50s support ⢠Resistance near $60â63 Support Level: $50.13â$50.41 Resistance Level: $59â$63 Short-term weakness: price sits just below the last month SMA and has fallen from January highs, holding low-$50s support but needing to reclaim $59â$63 to reverse.
Sentiment & News
Key News Insights: ⢠Product momentum ⢠Analyst optimism ⢠Institutional selling Inspire exhibits clear product and R&D momentum with growing analyst optimism but faces valuation debate and some institutional selling that heighten near-term execution and reimbursement risk. #R&Dâ
AI Summary
INSP has shifted from a pure growth story to a binary execution-and-reimbursement betâits strong unit economics, high gross margins and cash runway materially reduce financing risk but near-term adoption frictions (elongated V rollout, inventory/IVâV transition) and reimbursement uncertainty drove lowered FY26 guidance and amplify downside. Investors should size positions around clear, sustained reimbursement wins (C-code/OPPS clarity) and consistent V implant growth/inventory turnover before adding exposure, and consider trimming or avoiding until those operational milestones are met.
Description
Inspire Medical Systems develops and markets minimally invasive treatments for obstructive sleep apnea in the United States and abroad. Its core product is an implanted hypoglossal nerve neurostimulation system used to treat moderate to severe OSA, and the company is progressing a closed-loop device that monitors respiration and delivers targeted stimulation to keep the airway open. The company was incorporated in 2007 and is based in Golden Valley, Minnesota.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Dec 2 | Dec 9 | INSP | Inspire Medical Systems, Inc. | Compelling short-term momentum with a 75% price surge over 21 days, driven by Q3 earnings beat, raised EPS guidance, growing Inspire V system adoption, positive reimbursement changes for 2026, but tempered by pending securities class-action risks and margin compression. | Closed | +5.0% |